an investigational sugar-engineered antibody directed to the immune checkpoint TIGIT
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
SGNTGT-001: Advanced solid tumors and lymphomas (SEA-TGT ± sasanlimab)
High-level synopsis of SEA-TGT and ongoing clinical trials
Detailed information about SEA-TGT clinical trials